Possible overvaluation of Nanjing Vazyme Biotech's shares du...
Possible overvaluation of Nanjing Vazyme Biotech's shares due to declining revenues, despite lift in share price and P/S ratio. Investors may be paying a premium for the stock, which may not be sustainable.
Nanjing Vazyme Biotech Co.,Ltd's (SHSE:688105) 25% Price Boost Is Out Of Tune With Revenues
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment